Wugen is a clinical stage immuno-oncology cell therapy company, developing off-the-shelf NK and CAR-T cell therapies for the treatment of both solid tumor and heme malignancies.
Our lead program, WU-NK-101 is being tested in Phase 1b clinical trials. As the first product derived from our memory NK cell therapy platform, WU-NK-101 has shown robust efficacy (and safety) in AML patients.
Location: United States, California, San Diego
Employees: 11-50
Total raised: $172M
Founded date: 2018
Investors 4
| Date | Name | Website |
| 24.04.2022 | Aisling Ca... | aislingcap... |
| - | Lightchain... | lightchain... |
| - | Alpha Wave... | alphawaveg... |
| 16.07.2021 | Abingworth... | abingworth... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.07.2021 | Series B | $172M | - |
Mentions in press and media 12
| Date | Title | Description | Source |
| 16.06.2022 | WuXi ATU and Wugen Announce Manufacturing Partnership to Exp... | PHILADELPHIA and ST. LOUIS, MO and SAN DIEGO, June 16, 2022 /PRNewswire/ -- WuXi Advanced Therapies ... | en.prnasia... |
| 20.07.2021 | Wugen Takes $172M For Tumor Treatments | San Diego-based Wugen, a biotechnology company which is developing treatments for solid tumors, rece... | socaltech.... |
| 17.07.2021 | Wugen Raises $172M in Series B Funding | Wugen, a Sant Louis MO- and San Diego CA-based clinical stage biotechnology company, raised $172M in... | finsmes.co... |
| 15.07.2021 | Wugen Raises $172 Million to Advance Clinical Stage Memory N... | Wugen, Inc., a clinical stage biotechnology company developing a pipeline of off-the-shelf cell ther... | marketscre... |
| 15.07.2021 | Wugen unveils $172M to take natural killer cell therapies to... | The first wave of cell therapies included personalized cancer treatments made from a patient’s own i... | medcitynew... |
| 15.07.2021 | New CEO, check. $172M round, check. Wugen's off-the-shelf ce... | Dan Kemp (Wugen) When Dan Kemp was plotting his next move after Takeda, he was “blown away” by data... | fiercebiot... |
| 15.07.2021 | Wugen Inc. announced that it has received $172 million in fu... | Wugen Inc. announced that it has raised $172,000,000 in a round of funding co-led by new investors A... | marketscre... |
| 15.07.2021 | New CEO, check. $172M round, check. Wugen's off-the-shelf ce... | Dan Kemp (Wugen) When Dan Kemp was plotting his next move after Takeda, he was “blown away” by data... | fiercebiot... |
| 22.02.2021 | Wugen Announces Exclusive License Agreement for their Memory... | ST. LOUIS, Feb. 22, 2021 /PRNewswire/ -- Wugen Inc., a biotechnology company developing novel, uni... | prnewswire... |
| 29.01.2020 | Makers of novel cell/gene therapy say off-the-shelf approach... | In a recent interview in San Francisco, Wotton and another biopharma executive pointed to a solution... | medcitynew... |
Show more